JP2005511785A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511785A5 JP2005511785A5 JP2003552714A JP2003552714A JP2005511785A5 JP 2005511785 A5 JP2005511785 A5 JP 2005511785A5 JP 2003552714 A JP2003552714 A JP 2003552714A JP 2003552714 A JP2003552714 A JP 2003552714A JP 2005511785 A5 JP2005511785 A5 JP 2005511785A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- carbamoyl
- dioxo
- methylthio
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 17
- -1 N-{(R) -α- [N-((R) -1-carboxy-2-methylthioethyl) carbamoyl ] -4-hydroxybenzyl} carbamoylmethoxy Chemical group 0.000 claims 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- HFLYCKJGBPCISD-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)ethylsulfanyl]-3-[4-[2-(4-methylsulfonyloxyphenoxy)ethyl]phenyl]propanoic acid Chemical compound C1=CC(OS(=O)(=O)C)=CC=C1OCCC(C=C1)=CC=C1CC(C(O)=O)SCCC1=CC=C(Cl)C=C1 HFLYCKJGBPCISD-UHFFFAOYSA-N 0.000 claims 2
- PGZGQQFVPOZCAQ-UHFFFAOYSA-N 2-[2-(4-hydroxyphenyl)ethylsulfanyl]-3-[4-[2-(4-methylsulfonyloxyphenoxy)ethyl]phenyl]propanoic acid Chemical compound C1=CC(OS(=O)(=O)C)=CC=C1OCCC(C=C1)=CC=C1CC(C(O)=O)SCCC1=CC=C(O)C=C1 PGZGQQFVPOZCAQ-UHFFFAOYSA-N 0.000 claims 2
- 229940125922 IBAT inhibitor Drugs 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- CICPSCXBPAGDJY-UHFFFAOYSA-N 1,2,5-benzothiadiazepine Chemical class S1N=CC=NC2=CC=CC=C12 CICPSCXBPAGDJY-UHFFFAOYSA-N 0.000 claims 1
- GYEWMDUUKDWGNS-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)ethylsulfanyl]-3-[4-[2-(4-methylsulfonyloxyphenoxy)ethyl]phenyl]propanoic acid Chemical class C1=CC(OS(=O)(=O)C)=CC=C1OCCC(C=C1)=CC=C1CC(C(O)=O)SCCC1=CC=C(F)C=C1 GYEWMDUUKDWGNS-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000013078 crystal Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104333A SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005743 WO2003051826A1 (en) | 2001-12-19 | 2002-12-18 | 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006077296A Division JP2006241162A (ja) | 2001-12-19 | 2006-03-20 | ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511785A JP2005511785A (ja) | 2005-04-28 |
| JP2005511785A5 true JP2005511785A5 (https=) | 2006-01-05 |
| JP3810770B2 JP3810770B2 (ja) | 2006-08-16 |
Family
ID=20286432
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003552714A Expired - Fee Related JP3810770B2 (ja) | 2001-12-19 | 2002-12-18 | ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体 |
| JP2006077296A Withdrawn JP2006241162A (ja) | 2001-12-19 | 2006-03-20 | ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006077296A Withdrawn JP2006241162A (ja) | 2001-12-19 | 2006-03-20 | ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7276539B2 (https=) |
| EP (1) | EP1458677B1 (https=) |
| JP (2) | JP3810770B2 (https=) |
| KR (1) | KR20040068589A (https=) |
| CN (1) | CN100343229C (https=) |
| AR (1) | AR038046A1 (https=) |
| AT (1) | ATE428691T1 (https=) |
| AU (1) | AU2002352426A1 (https=) |
| BR (1) | BR0215090A (https=) |
| CA (1) | CA2470066C (https=) |
| CO (1) | CO5590908A2 (https=) |
| DE (1) | DE60232018D1 (https=) |
| ES (1) | ES2324025T3 (https=) |
| HU (1) | HUP0402093A3 (https=) |
| IL (1) | IL162378A0 (https=) |
| IS (1) | IS7303A (https=) |
| MX (1) | MXPA04005992A (https=) |
| NO (1) | NO20043084L (https=) |
| NZ (1) | NZ533365A (https=) |
| PL (1) | PL370623A1 (https=) |
| RU (1) | RU2004117776A (https=) |
| SE (1) | SE0104333D0 (https=) |
| TW (1) | TW200410678A (https=) |
| UA (1) | UA80407C2 (https=) |
| WO (1) | WO2003051826A1 (https=) |
| ZA (1) | ZA200404585B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL375074A1 (en) | 2002-06-20 | 2005-11-14 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| GB0314131D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314134D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0427524D0 (en) | 2004-12-16 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| GB0427701D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Therapeutic agents |
| AU2008221673B2 (en) * | 2007-03-08 | 2013-03-28 | Albireo Ab | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| WO1999029640A2 (en) | 1997-12-05 | 1999-06-17 | Eisai Co., Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| SE9801990D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| NZ515086A (en) * | 1999-04-28 | 2003-10-31 | Aventis Pharma Gmbh | Di-aryl acid derivatives as PPAR receptor ligands |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TW574193B (en) | 1999-12-03 | 2004-02-01 | Astrazeneca Ab | Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses |
| SE9904421D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | New compounds |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| KR20020081424A (ko) | 2000-03-09 | 2002-10-26 | 아벤티스 파마 도이칠란트 게엠베하 | Ｐｐａｒ 매개인자의 치료학적 용도 |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| TWI331143B (en) * | 2001-09-08 | 2010-10-01 | Astrazeneca Uk Ltd | Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| SE0201937D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| SE0201936D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| PL375074A1 (en) | 2002-06-20 | 2005-11-14 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| GB0314078D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314129D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314136D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314131D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2001
- 2001-12-19 SE SE0104333A patent/SE0104333D0/xx unknown
-
2002
- 2002-12-18 CA CA002470066A patent/CA2470066C/en not_active Expired - Fee Related
- 2002-12-18 AT AT02788144T patent/ATE428691T1/de not_active IP Right Cessation
- 2002-12-18 CN CNB028281225A patent/CN100343229C/zh not_active Expired - Fee Related
- 2002-12-18 IL IL16237802A patent/IL162378A0/xx unknown
- 2002-12-18 KR KR10-2004-7009348A patent/KR20040068589A/ko not_active Withdrawn
- 2002-12-18 PL PL02370623A patent/PL370623A1/xx unknown
- 2002-12-18 MX MXPA04005992A patent/MXPA04005992A/es not_active Application Discontinuation
- 2002-12-18 AU AU2002352426A patent/AU2002352426A1/en not_active Abandoned
- 2002-12-18 RU RU2004117776/04A patent/RU2004117776A/ru not_active Application Discontinuation
- 2002-12-18 EP EP02788144A patent/EP1458677B1/en not_active Expired - Lifetime
- 2002-12-18 HU HU0402093A patent/HUP0402093A3/hu unknown
- 2002-12-18 JP JP2003552714A patent/JP3810770B2/ja not_active Expired - Fee Related
- 2002-12-18 UA UA20040604534A patent/UA80407C2/uk unknown
- 2002-12-18 DE DE60232018T patent/DE60232018D1/de not_active Expired - Lifetime
- 2002-12-18 US US10/499,042 patent/US7276539B2/en not_active Expired - Fee Related
- 2002-12-18 ES ES02788144T patent/ES2324025T3/es not_active Expired - Lifetime
- 2002-12-18 TW TW091136517A patent/TW200410678A/zh unknown
- 2002-12-18 NZ NZ533365A patent/NZ533365A/en unknown
- 2002-12-18 WO PCT/GB2002/005743 patent/WO2003051826A1/en not_active Ceased
- 2002-12-18 BR BR0215090-5A patent/BR0215090A/pt not_active IP Right Cessation
- 2002-12-19 AR ARP020105003A patent/AR038046A1/es not_active Application Discontinuation
-
2004
- 2004-06-08 IS IS7303A patent/IS7303A/is unknown
- 2004-06-09 ZA ZA200404585A patent/ZA200404585B/en unknown
- 2004-07-16 NO NO20043084A patent/NO20043084L/no not_active Application Discontinuation
- 2004-07-16 CO CO04068143A patent/CO5590908A2/es not_active Application Discontinuation
-
2006
- 2006-03-20 JP JP2006077296A patent/JP2006241162A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005117792A (ru) | Терапевтические агенты | |
| JP2006045240A5 (https=) | ||
| RU2004116917A (ru) | Производные замещенной фенлпропионовой кислоты как агонисты активируемого пролифератором пероксисом альфа рецептора человека | |
| RU2008129204A (ru) | Применение ингибитора ibat для лечения или профилактики запора | |
| JP2006298925A (ja) | 脂肪性疾患の治療に有効なプロピオン酸誘導体 | |
| JP2005511785A5 (https=) | ||
| JP2007502806A5 (https=) | ||
| RU2004117776A (ru) | Производные 3-фенил-2-арилалкилтиопропионовой кислоты в качестве селективных антагонистов ppar-альфа | |
| JP2009504793A5 (https=) | ||
| JP2006527766A (ja) | カルボン酸誘導体の製剤上有用な塩 | |
| CN1805922A (zh) | 羧酸衍生物的药用盐 | |
| CN1551871A (zh) | 制备噻唑ppar-配体及其多晶型物的方法 | |
| EP1638930A1 (en) | Amine salts of (-)-2- ¬2-(4-hydroxyphenyl)ethyl|-thio -3-¬4-(2- 4-¬(methylsulfonyl)oxy|phenoxy ethyl)phenyl|propanoic acid and their use in medicine. | |
| RU2288912C2 (ru) | Ортозамещенные производные бензойной кислоты, способ и промежуточные соединения для их получения, фармацевтическая композиция на их основе и применение | |
| JP2003535840A5 (https=) | ||
| US20070099997A1 (en) | Potassium or sodium salt of (-)-2-{'2-(4-hydroxyphenyl) ethyl!-thio-3-'4-(2-{4-'(methylsulfonyl) oxy! phenoxy}ethyl) phenyl! propanoic acid and their use in medicine | |
| CN1835916A (zh) | 治疗脂质紊乱的2－乙氧基－3－苯基丙酸衍生物 | |
| JP2008524209A (ja) | （２ｓ）−２−エトキシ−３−（４−｛２−［ヘキシル（２−フェニルエチル）アミノ］−２−オキソエトキシ｝フェニル）プロパン酸のトリス（ヒドロキシメチル）メチルアミン塩またはエタノールアミン塩 |